Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Goodwill & Intangibles (2016 - 2025)

Lineage Cell Therapeutics' Goodwill & Intangibles history spans 16 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 81.35% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, down 81.35%, while the annual FY2025 figure was $10.7 million, 81.35% down from the prior year.
  • Goodwill & Intangibles reached $10.7 million in Q4 2025 per LCTX's latest filing, down from $42.4 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $76.8 million in Q2 2022 to a low of $10.7 million in Q1 2025.
  • Average Goodwill & Intangibles over 5 years is $52.1 million, with a median of $57.2 million recorded in 2024.
  • Peak YoY movement for Goodwill & Intangibles: surged 434.99% in 2024, then crashed 86.11% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $57.5 million in 2021, then skyrocketed by 33.61% to $76.8 million in 2022, then plummeted by 86.08% to $10.7 million in 2023, then soared by 434.99% to $57.2 million in 2024, then crashed by 81.35% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Goodwill & Intangibles are $10.7 million (Q4 2025), $42.4 million (Q3 2025), and $42.4 million (Q2 2025).